Le Meur Y - Search Results

1

A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.

Prémaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, Hoizey G, Le Guellec C, Marquet P. Prémaud A, et al. Among authors: le meur y, le guellec c. Clin Pharmacokinet. 2005;44(8):837-47. doi: 10.2165/00003088-200544080-00005. Clin Pharmacokinet. 2005. PMID: 16029068 Clinical Trial.

2

Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.

Le Guellec C, Büchler M, Giraudeau B, Le Meur Y, Gakoué JE, Lebranchu Y, Marquet P, Paintaud G. Le Guellec C, et al. Among authors: le meur y. Eur J Clin Pharmacol. 2002 Jan;57(11):805-11. doi: 10.1007/s00228-001-0389-2. Eur J Clin Pharmacol. 2002. PMID: 11868803 Clinical Trial.

3

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G. Lebranchu Y, et al. Among authors: le pogamp p, le meur y. Am J Transplant. 2002 Jan;2(1):48-56. doi: 10.1034/j.1600-6143.2002.020109.x. Am J Transplant. 2002. PMID: 12095056 Free article. Clinical Trial.

4

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.

Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. Anglicheau D, et al. Among authors: le meur y. Clin Pharmacol Ther. 2004 May;75(5):422-33. doi: 10.1016/j.clpt.2004.01.009. Clin Pharmacol Ther. 2004. PMID: 15116055

5

Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring.

Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P. Prémaud A, et al. Among authors: le meur y. Ther Drug Monit. 2004 Dec;26(6):609-19. doi: 10.1097/00007691-200412000-00005. Ther Drug Monit. 2004. PMID: 15570184

6

Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.

Prémaud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, Toupance O, Marquet P. Prémaud A, et al. Among authors: le meur y. Ther Drug Monit. 2005 Jun;27(3):354-61. doi: 10.1097/01.ftd.0000162231.90811.38. Ther Drug Monit. 2005. PMID: 15905807

7

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rérolle JP, Marquet P. Le Meur Y, et al. Clin Pharmacol Ther. 2006 Jul;80(1):51-60. doi: 10.1016/j.clpt.2006.03.012. Clin Pharmacol Ther. 2006. PMID: 16815317

8

A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.

Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P. Picard N, et al. Among authors: le meur y. Br J Clin Pharmacol. 2006 Oct;62(4):477-84. doi: 10.1111/j.1365-2125.2006.02509.x. Br J Clin Pharmacol. 2006. PMID: 16995869 Free PMC article.

9

CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.

Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G. Abou-Ayache R, et al. Among authors: le meur y. Nephrol Dial Transplant. 2008 Jun;23(6):2024-32. doi: 10.1093/ndt/gfm873. Epub 2008 Jan 16. Nephrol Dial Transplant. 2008. PMID: 18199693 Clinical Trial.

10

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.

Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Wallemacq P, et al. Among authors: le meur y. Ther Drug Monit. 2009 Apr;31(2):139-52. doi: 10.1097/FTD.0b013e318198d092. Ther Drug Monit. 2009. PMID: 19177031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters